News
BPA’s Real Threat May Be After It Has Metabolized
Bisphenol A (BPA) is a synthetic chemical widely used in the making of plastic products ranging from bottles and food can linings to toys and water supply lines. When these plastics degrade, BPA is released into the environment and routinely ingested. New research from the University of California, San Diego School of Medicine suggests it’s the metabolic changes that take place once BPA is broken down inside the body that pose the greater health threat.
UC San Diego Sulpizio Cardiovascular Center Named One of Nation’s Top Heart Hospitals
UC San Diego Sulpizio Cardiovascular Center has been named one of the nation’s 50 Top Cardiovascular Hospitals by Truven Health Analytics. The Truven study examined the performance of more than 1,000 hospitals by analyzing outcomes for patients with heart failure and heart attacks and for those who received coronary bypass surgery and percutaneous coronary interventions such as angioplasties.
Blocking Tumor-Induced Inflammation Impacts Cancer Development
Researchers at the University of California, San Diego School of Medicine report the discovery of microbial–dependent mechanisms through which some cancers mount an inflammatory response that fuels their development and growth.
UC San Diego Gorder Walk Raises Funds for Melanoma Research Oct. 6
Briana Bilbray is only 25, yet she is undergoing the fight of her life—against melanoma. In addition to waging a battle against the disease, Briana is also working to raise awareness of the risks of melanoma, particularly among young people.
Common RNA Pathway Found in ALS and Dementia
Two proteins previously found to contribute to ALS, also known as Lou Gehrig’s disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.
UCSD-based Cancer Consortium Receives 5-Year, $20 Million Grant Renewal
An international consortium of scientists studying chronic lymphocytic leukemia (CLL), based at the University of California, San Diego School of Medicine, has been awarded a 5-year, $20 million grant by the National Cancer Institute, part of the National Institutes of Health. The grant is the second renewal of funding for a broad-based effort designed to better understand the pathology of CLL – the most common form of leukemia in the Western world – and develop new drugs and treatments.
September 27, 2012 • Awards, General, Health, Science and Engineering
New Way of Fighting High Cholesterol Upends Assumptions
Atherosclerosis has been presumed to be the consequence of complicated interactions between overabundant cholesterol and resulting inflammation in the heart and blood vessels. Researchers at the University of California, San Diego School of Medicine, with colleagues at institutions across the country, say the relationship is not exactly what it appears, and that a precursor to cholesterol actually suppresses inflammatory response genes. This precursor molecule could provide a new target for drugs designed to treat atherosclerosis.
September 27, 2012 • General, Health, Science and Engineering
Single-Site Laparoscopic Surgery Reduces Pain of Tumor Removal
Researchers at the University of California, San Diego School of Medicine have found that recovery from an emerging, minimally invasive surgical technique called Laparo-Endoscopic Single-Site Surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery.
September 27, 2012 • General, Health, Science and Engineering
Limited Tickets Available for Opening of Sold-Out “The Atlantic Meets the Pacific” Forum
For the second consecutive year, The Atlantic, a magazine that has played a central role in shaping the national debate on current affairs and cultural trends for 150 years, has chosen to partner with UC San Diego to co-host a forum of national prominence on campus.
September 27, 2012 • Events, Health, Science and Engineering, SDSC
Clinical Trial Evaluates Synthetic Cannabinoid as Brain Cancer Treatment
Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.
September 25, 2012 • General, Health, Science and Engineering
Top Stories
Excess Protein Linked to Development of Parkinson’s Disease
Working Alone Won’t Get You Good Grades
Shu Chien Named San Diego Festival of Science & Engineering Chief Engineer
UC San Diego Named to Princeton Review’s List of Best Value Colleges for 2013
UC San Diego Ranks No. 13 Nationally on the Peace Corps Top Colleges List
